From left, University of Erlangen-Nuremberg professor Frank Roemer, Boston University professor Ali Guermazi and Kolon TissueGene CEO Moon J. Noh pose at OARSI 2026. Courtesy of Kolon TissueGene
Kolon TissueGene announced that it presented long-term follow-up data for TG-C at the World Congress of the Osteoarthritis Research Society International (OARSI), held April 23 to 26 in West Palm Beach, Florida.
OARSI is an international organization focused on osteoarthritis research, and its annual congress brings together clinical and scientific experts to share emerging data.
At the congress, the company presented long-term follow-up data of up to 17 years for TG-C, along with a subgroup analysis from a Phase 2 study evaluating outcomes by body mass index (BMI).
As of July 31, 2025, a total of 219 participants — including five from Phase 1, 33 from Phase 2 and 181 from Phase 3 — had been followed for up to about 17 years in a long-term study. Based on the available data, no new safety signals have been identified so far, and no tumor cases have been deemed related to TG-C. A subgroup of elderly patients monitored for more than a decade also showed no new safety findings during the observation period.
A subgroup analysis from a Phase 2 study showed reductions in pain scores in both lower-BMI (below 30) and higher-BMI (30 or above) groups compared with baseline.
TG-C is an investigational cell and gene therapy and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.
The company plans to report topline results in July following completion of data analysis.
Statements from company executives reflect their views regarding the data and the potential of TG-C. However, further controlled studies are required to confirm these observations.
TG-C is being studied as a treatment for knee osteoarthritis, a condition that poses a significant global health burden. Ongoing research is seeking therapies that may address both symptoms and the underlying disease process.
Source: Korea Times News
